• Product name
    Anti-VLDL Receptor antibody
    See all VLDL Receptor primary antibodies
  • Description
    Rabbit polyclonal to VLDL Receptor
  • Host species
  • Tested applications
    Suitable for: WBmore details
  • Species reactivity
    Reacts with: Mouse, Human
    Predicted to work with: Rat, Rabbit, Cow
  • Immunogen

    Synthetic peptide conjugated to KLH derived from within residues 500 - 600 of Human VLDL Receptor.

    (Peptide available as ab102057.)

  • Positive control
    • This antibody gave a positive signal in Human ovary tissue lysate.


Our Abpromise guarantee covers the use of ab92943 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 µg/ml. Detects a band of approximately 130 kDa (predicted molecular weight: 96 kDa).


  • Function
    Binds VLDL and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Binding to Reelin induces tyrosine phosphorylation of Dab1 and modulation of Tau phosphorylation.
  • Tissue specificity
    Abundant in heart and skeletal muscle; also ovary and kidney; not in liver.
  • Involvement in disease
    Defects in VLDLR are the cause of cerebellar ataxia mental retardation and dysequilibrium syndrome type 1 (CMARQ1) [MIM:224050]; also known as dysequilibrium syndrome (DES) or non-progressive cerebellar disorder with mental retardation. CMARQ1 is a congenital, non-progressive cerebellar ataxia associated with disturbed equilibrium, delayed ambulation, mental retardation and cerebellar hypoplasia. Additional features include short stature, strabismus, pes planus and, rarely, seizures.
  • Sequence similarities
    Contains 3 EGF-like domains.
    Contains 8 LDL-receptor class A domains.
    Contains 6 LDL-receptor class B repeats.
  • Post-translational
    Ubiquitinated at Lys-839 by MYLIP leading to degradation.
  • Cellular localization
    Membrane. Membrane > clathrin-coated pit.
  • Information by UniProt
  • Database links
  • Alternative names
    • FLJ35024 antibody
    • Very low density lipoprotein receptor antibody
    • Very low-density lipoprotein receptor antibody
    • VLDL R antibody
    • VLDL receptor antibody
    • VLDL-R antibody
    • VLDLR antibody
    • VLDLR_HUMAN antibody
    • VLDLRCH antibody
    see all


  • Anti-VLDL Receptor antibody (ab92943) at 1 µg/ml + Human ovary tissue lysate - total protein (ab30222) at 10 µg

    Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 96 kDa
    Observed band size: 130 kDa (why is the actual band size different from the predicted?)
    Additional bands at: 24 kDa, 63 kDa. We are unsure as to the identity of these extra bands.

    Exposure time: 16 minutes

    The predicted molecular weight of VLDL Receptor is 96 kDa (SwissProt), however we expect to observe a banding pattern at 130 kDa. VLDL Receptor contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted. Abcam welcomes customer feedback and would appreciate any comments regarding this product and the data presented above.


This product has been referenced in:
  • Shin KC  et al. Macrophage VLDLR mediates obesity-induced insulin resistance with adipose tissue inflammation. Nat Commun 8:1087 (2017). Read more (PubMed: 29057873) »
  • Okoro EU  et al. A Subregion of Reelin Suppresses Lipoprotein-Induced Cholesterol Accumulation in Macrophages. PLoS One 10:e0136895 (2015). Read more (PubMed: 26317415) »

See all 4 Publications for this product

Customer reviews and Q&As

From your description it sounds like you are seeing something like what we show on the datasheet, a band at 130 kDa that we think is the receptor, and cross-reactivity with smaller proteins. The "predicted" size of 96 kDa is just that, a prediction bas...

Read More

Regarding a western blot protocol modification for the VLDLr antibody ab92943, this antibody does not require anything unusual, and I expect your protocol is fine if it is working for other antibodies. However, I recommend having a look at a recent cus...

Read More
Abcam guarantees this product to work in the species/application used in this Abreview.
Western blot
Mouse Tissue lysate - whole (Kidney, Testes, Cerebellum and spleen (see figure))
Loading amount
15 µg
Kidney, Testes, Cerebellum and spleen (see figure)
Gel Running Conditions
Reduced Denaturing (4-12% Bis-Tris gel (Novex))
Blocking step
Milk, serum (see figure) and BSA tested as blocking agent for 30 minute(s) · Concentration: 5% · Temperature: 25°C

Abcam user community

Verified customer

Submitted Oct 30 2012

I am very pleased to hear you would like to accept our offer and test ab92943 in mouse samples.

Expiration date: 1st Feb 2012

This code will give you: 1 free primary antibody before the expiration...

Read More

Thank you very much for yourenquiry.

I am sorry to confirm thatour knowledge, ab92943 has not been tested in mouse. It is predicted to react, due to high sequence alignment of the immmunogen with the mouse VLDL Receptor sequence. However, I ...

Read More

Thank you for contacting us.

As we had spoken of I have instructed our products team to add the blocking peptide for this ab92943. The product number is ab102057 and can be found at the following link: https://www.abcam.com/VLDL-Receptor...

Read More

Thank you for your enquiry.

This product has only been tested withHuman samples usingwestern blot (WB). The cross reactivity with rat is solely based on homology sequence (94% homology) with the immunogen.Therefore, I am afraid that we will ...

Read More


Sign up